598 related articles for article (PubMed ID: 16418784)
1. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
[TBL] [Abstract][Full Text] [Related]
2. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
3. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
5. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
7. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
8. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
Body JJ; Gaich GA; Scheele WH; Kulkarni PM; Miller PD; Peretz A; Dore RK; Correa-Rotter R; Papaioannou A; Cumming DC; Hodsman AB
J Clin Endocrinol Metab; 2002 Oct; 87(10):4528-35. PubMed ID: 12364430
[TBL] [Abstract][Full Text] [Related]
10. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
Rosen CJ; Chesnut CH; Mallinak NJ
J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
[TBL] [Abstract][Full Text] [Related]
11. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.
Lindsay R; Cosman F; Lobo RA; Walsh BW; Harris ST; Reagan JE; Liss CL; Melton ME; Byrnes CA
J Clin Endocrinol Metab; 1999 Sep; 84(9):3076-81. PubMed ID: 10487668
[TBL] [Abstract][Full Text] [Related]
12. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
13. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
Harris ST; Eriksen EF; Davidson M; Ettinger MP; Moffett AH; Baylink DJ; Crusan CE; Chines AA
J Clin Endocrinol Metab; 2001 May; 86(5):1890-7. PubMed ID: 11344179
[TBL] [Abstract][Full Text] [Related]
14. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
15. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
Tuppurainen MT; Komulainen M; Kröger H; Honkanen R; Jurvelin J; Puntila E; Heikkinen AM; Alhava E; Saarikoski S
Osteoporos Int; 1998; 8(1):32-8. PubMed ID: 9692075
[TBL] [Abstract][Full Text] [Related]
16. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
Boonen S; Marin F; Obermayer-Pietsch B; Simões ME; Barker C; Glass EV; Hadji P; Lyritis G; Oertel H; Nickelsen T; McCloskey EV;
J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
18. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Honkanen R; Saarikoski S
Osteoporos Int; 2000; 11(3):211-8. PubMed ID: 10824236
[TBL] [Abstract][Full Text] [Related]
19. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
[TBL] [Abstract][Full Text] [Related]
20. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
Tiraş MB; Noyan V; Yildiz A; Biberoğlu K
Climacteric; 2000 Jun; 3(2):92-101. PubMed ID: 11910657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
